ClinicalTrials.gg
RecruitingNCT07712107Updated Aug 14, 2026

A Study on Gastrointestinal Cancer Screening Using a Multi-Targeted Combined Detection Model

An interventional study of Multi-target blood methylation + fecal FIT + fecal calprotectin in Gastrointestinal Tumors, sponsored by Xijing Hospital. Recruiting at 6 sites in China. Open to participants aged 45 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Xijing Hospital · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10,000
Allocation
Randomized
Ages
45 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Digestive System Neoplasms with a site in China — 35 open to participants now, 40 under way, 4 of them phase 3. Digestive System Neoplasms · China.

Planned enrollment
Largest of 64
10,000 · median 60
Started
2026
with 7 others
No phase
10 of 75
5 open now
Primary completion
2035-12
later than 39 of 39 live
Registered
73rd of 75
by date

Among the 75 studies in Digestive System Neoplasms with a site in China, this one has the largest planned enrollment of the 64 interventional ones that give a count, is one of 8 that started in 2026, is one of 10 with no phase, reaches primary completion later than 39 of the 39 other live ones, and was the 73rd registered.

Digestive System Neoplasms

195 studies on the registry are indexed under Digestive System Neoplasms; 57 are open to participants now.

Browse Digestive System Neoplasms studies →

Open to participants now

35 of the 75 studies in Digestive System Neoplasms with a site in China are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 52 Digestive System Neoplasms studies recruiting now, 27 (52%) set no upper age limit and 17 (33%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 45 Years to 74 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Digestive System Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, randomized controlled trial. The plan is to enroll eligible participants and randomly assign them to two groups: one group will undergo testing using a combined model of "multi-target blood methylation + fecal FIT + fecal calpetin"; those with positive results will immediately undergo standard gastrointestinal endoscopy, while those with negative results will enter routine observation; the other group will undergo only routine observation and follow-up. All enrolled participants will undergo a 5-year prospective follow-up, during which information on gastrointestinal cancer incidence and mortality will be collected through regular contact and review of medical records. The primary endpoint of the study is the difference in 5-year all-gastrointestinal cancer mortality between the two groups.This project aims to use a randomized controlled trial design to evaluate whether an active screening strategy based on a combined model can effectively reduce the population-level mortality from gastrointestinal cancers compared to routine surveillance. The objective is to provide high-level evidence for establishing a new screening strategy that reduces the disease burden and delivers public health benefits. It lays the foundation for validating novel biomarkers and exploring the biological and behavioral factors that influence screening outcomes, and offers clear decision-making support for optimizing China's comprehensive prevention and control system for gastrointestinal cancers.

03

Conditions studied

  • Gastrointestinal Tumors
04

Who can participate

Ages eligible
45 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be between 45 and 74 years of age at the time of enrollment;
  • Participants must agree to be randomly assigned to different screening and follow-up strategies;
  • Participants must agree to undergo a five-year follow-up in accordance with the protocol;
  • Participants must be willing to participate and sign an form.

Exclusion criteria

Exclusion Criteria:

  • Underwent upper gastrointestinal endoscopy screening within the past year;
  • History of any type of malignant tumor;
  • Concurrent severe medical conditions that reduce the benefits of screening, such as severe pulmonary disease, kidney disease, liver disease, cardiovascular and cerebrovascular diseases, and hematological disorders;
  • Other situations where a physician determines that endoscopic screening poses excessive risk (e.g., hemodynamic instability) or offers no benefit (e.g., short );
  • Pregnant or breastfeeding women.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10,000 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Diagnostic Test: Multi-target blood methylation + fecal FIT + fecal calprotectin

  • No intervention
    control group

Interventions

  • Diagnostic testMulti-target blood methylation + fecal FIT + fecal calprotectin

    The intervention group underwent testing using a combined model of "multi-target blood methylation + fecal FIT + fecal calprotectin"; those with positive results subsequently underwent standard gastrointestinal endoscopy, while those with negative results were placed under routine observation.

06

What researchers measure

Primary outcomes

  1. Differences in cancer-specific mortality rates across the entire gastrointestinal tract between the two groups.

    Time frame: Participants will be followed up for 5 years from the time of enrollment to collect data on gastrointestinal cancer-related deaths in both groups, with the final assessment of the primary outcome conducted at the 5-year mark after enrollment.

Secondary outcomes

  1. The incidence of gastrointestinal cancer in the two groups

    Time frame: Comparison of the incidence of new gastrointestinal cancers among the two groups of participants within five years of enrollment

  2. Sensitivity and specificity of the combined screening model for detecting gastrointestinal cancers in the intervention group

    Time frame: Baseline

  3. All-cause mortality in the two groups

    Time frame: All-cause mortality among all participants within 5 years of enrollment

  4. Detection rate of precancerous lesions and early-stage gastrointestinal tumors

    Time frame: At baseline and during foDetection of early-stage lesions llow-up within 5 years of enrollment

  5. Incidence of endoscopy-related complications

    Time frame: Incidence of various endoscopy-related complications observed within 5 years

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Applications shall be submitted to the principal investigator upon study completion. Applicants are required to provide a data analysis plan, and data sharing will be approved after assessment.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2035, 114 months after the start.

Of 24 interventional studies with no phase under Digestive System Neoplasms, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 15. This study's planned 114 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 17, 2026
StartActual
Jun 15, 2026
Primary completionEst.
Dec 31, 2035
CompletionEst.
Dec 31, 2035
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07712107
Lead sponsor
Xijing Hospital
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Jun 15, 2026
Primary completion
Dec 31, 2035 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Aug 14, 2026

Study contacts

Yongzhan Nie
Contact
zhengrong4956@163.com
+86 198 2975 8242

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion